# Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma

> **NCT01211275** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 32 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **BIOLOGICAL:** axitinib
- **DRUG:** chemotherapy

## Key facts

- **NCT ID:** NCT01211275
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-22
- **Primary completion:** 2012-11-13
- **Final completion:** 2013-05-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01211275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01211275, "Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01211275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*